MAPT and Alzheimer disease: First, in rodent models of AD, the GLP-1 analog Liraglutide was shown to promote neuronal survival, increase synaptic function, reduce neuroinflammation, amyloid plaque and hyperphosphorylated Tau, and support learning and memory (McClean et al., 2011, 2015; Hansen et al., 2016a; Qi et al., 2016; Chen et al., 2017; Holscher, 2018).